Pfizer invests in biopharma company Caribou Biosciences
07 Jul 2023
Cell TherapyPhase 1Fast TrackImmunotherapyGene Therapy
Preview
Source: Pharmaceutical Technology
Caribou is evaluating CB-011 in a Phase I CaMMouflage clinical trial for relapsed or refractory multiple myeloma. Credit: Nemes Laszlo via Shutterstock.com.
Preview
Source: Pharmaceutical Technology
Pfizer has invested $25m in the clinical-stage, clustered, regularly interspaced, short palindromic repeats, genome-editing biopharmaceutical firm, Caribou Biosciences.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsEngineering Microorganisms into Powerful Micromachines: Can Synthetic Biology Foster Bio-Revoluti... GlobalData
Preview
Source: Pharmaceutical Technology
ReportsImmuno-oncology in Pharmaceuticals: CAR-T cell-based compositions GlobalData
View allCompanies IntelligencePfizer IncCaribou Biosciences IncView all
Pfizer global product development multiple myeloma vice-president and development head Sriram Krishnaswami will now join the scientific advisory board of Caribou.
The investment will be used to progress an immune-cloaked allogeneic CAR-T cell therapy, CB-011.
The company is currently evaluating the cell therapy in a Phase I CaMMouflage clinical trial for relapsed or refractory multiple myeloma.
The US Food and Drug Administration granted fast track designation for CB-011 in April 2023.
The complete ownership and control of the pipeline comprising allogeneic CAR-T and CAR-NK cell therapies will be retained by Caribou.
“We are actively advancing our allogeneic CAR-T cell therapy pipeline and look forward to providing updates from all of our programmes over the next six months, including six-month dose escalation data from our ANTLER Phase I clinical trial for CB-010, dose escalation updates on our CaMMouflage Phase I clinical trial for CB-011, and submission of an investigational new drug application for CB-012.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free Whitepaper
Optimise your cell therapy process: a guide to cell thawing
Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.
This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
By Cytiva Thematic
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.